Press release from Business Wire
AstraZeneca Provides $86.6 Million in Prescription Savings to Texas Residents in 2010
Monday, January 31, 2011
WILMINGTON, Del. (Business Wire) -- AstraZeneca (NYSE:AZN) announced today that it provided $86.6 million in savings last year to 72,085 patients in Texas who participate in its AZ&Me prescription savings programs. Texas residents filled a total of 485,441 prescriptions under these programs that provide AstraZeneca medicines at no cost to eligible patients.
“While the economy appears to be getting stronger, we are still seeing record numbers of patients in our prescription savings programs and they are staying in the programs longer,” said Rich Fante, President AstraZeneca U.S. & Regional VP North America.
Nationally, AstraZeneca helped 545,937 patients fill more than 4.1 million prescriptions for $947 million in savings through its AZ&Me prescription savings programs in 2010.
AstraZeneca provides free medicines to patients through its AZ&Me prescription savings programs in three ways:
- Individuals: AstraZeneca provides free medicines to qualifying individuals without prescription drug coverage who make up to $30,000 per year and families of four with $60,000 annual household income.
- Part D beneficiaries: AstraZeneca provides free medicines for qualifying Medicare Part D patients who make up to $30,000 per year or couples who make up to $40,000 per year. Medicare Part D patients can have their filled prescription mailed to their home or physician's office.
- Healthcare facilities: AstraZeneca provides free medicines to qualifying non-profit organizations, such as disproportionate share hospitals, community health centers and community free clinics. This program connects patients to the medicines they need at the same time and place they receive their treatment.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business.
For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).
Katie Lubenow, 302-885-9960